How interacting pathways are regulated by miRNAs in breast cancer subtypes

[1]  Yung-Hyun Choi,et al.  Metabolic Pathway Signatures Associated with Urinary Metabolite Biomarkers Differentiate Bladder Cancer Patients from Healthy Controls , 2016, Yonsei medical journal.

[2]  Daming Zhang,et al.  miR‐577 inhibits glioblastoma tumor growth via the Wnt signaling pathway , 2016, Molecular carcinogenesis.

[3]  T. Ochiya,et al.  Novel combination of serum microRNA for detecting breast cancer in the early stage , 2016, Cancer science.

[4]  Gianluca Bontempi,et al.  TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data , 2015, Nucleic acids research.

[5]  S. Pinder,et al.  PAK4 promotes kinase-independent stabilization of RhoU to modulate cell adhesion , 2015, The Journal of cell biology.

[6]  Liyan Wang,et al.  Inhibition effect of miR-577 on hepatocellular carcinoma cell growth via targeting β-catenin. , 2015, Asian Pacific journal of tropical medicine.

[7]  Aiko Sueta,et al.  Prognostic role of PIK3CA mutations of cell‐free DNA in early‐stage triple negative breast cancer , 2015, Cancer science.

[8]  M. Manns,et al.  MicroRNAs in Serum and Bile of Patients with Primary Sclerosing Cholangitis and/or Cholangiocarcinoma , 2015, PloS one.

[9]  P. Vineis,et al.  Differentially methylated microRNAs in prediagnostic samples of subjects who developed breast cancer in the European Prospective Investigation into Nutrition and Cancer (EPIC-Italy) cohort. , 2015, Carcinogenesis.

[10]  N. Kanaya,et al.  From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer? , 2015, The Journal of Steroid Biochemistry and Molecular Biology.

[11]  T. Zhu,et al.  Autocrine human growth hormone stimulates the tumor initiating capacity and metastasis of estrogen receptor-negative mammary carcinoma cells. , 2015, Cancer letters.

[12]  Gianluca Bontempi,et al.  Integrative Analysis with Monte Carlo Cross-Validation Reveals miRNAs Regulating Pathways Cross-Talk in Aggressive Breast Cancer , 2015, BioMed research international.

[13]  F. Lallemand,et al.  MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers? , 2015, BMC Cancer.

[14]  A. Munitz,et al.  MicroRNA profiling reveals opposing expression patterns for miR-511 in alternatively and classically activated macrophages , 2015, The Journal of asthma : official journal of the Association for the Care of Asthma.

[15]  K. Akashi,et al.  Downregulation of CXCR4 in Metastasized Breast Cancer Cells and Implication in Their Dormancy , 2015, PloS one.

[16]  S. Lees-Miller,et al.  Low ATM protein expression in malignant tumor as well as cancer-associated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer , 2015, Breast Cancer Research.

[17]  You-cai Zhao,et al.  Expression Profiles and Clinical Significance of MicroRNAs in Papillary Renal Cell Carcinoma , 2015, Medicine.

[18]  M. Detmar,et al.  Characterization of macrophage - cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer , 2015, Scientific Reports.

[19]  Y. Zhan,et al.  A novel biphenyl urea derivate inhibits the invasion of breast cancer through the modulation of CXCR4 , 2015, Journal of cellular and molecular medicine.

[20]  M. Polenaković,et al.  Proteomics analysis of urine reveals acute phase response proteins as candidate diagnostic biomarkers for prostate cancer , 2015, Proteome Science.

[21]  A. Psyrri,et al.  p85 Protein Expression is Associated with Poor Survival in HER2-Positive Patients with Advanced Breast Cancer Treated with Trastuzumab , 2015, Pathology & Oncology Research.

[22]  Jian-guo Shen,et al.  FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients , 2015, Annals of Surgical Oncology.

[23]  Yong Han,et al.  miR‐99a directly targets the mTOR signalling pathway in breast cancer side population cells , 2014, Cell proliferation.

[24]  M. Quindós-Varela,et al.  Circulating MicroRNAs in blood of patients with prostate cancer. , 2014, Actas urologicas espanolas.

[25]  T. Koru-Sengul,et al.  A Novel MAPK–microRNA Signature Is Predictive of Hormone-Therapy Resistance and Poor Outcome in ER-Positive Breast Cancer , 2014, Clinical Cancer Research.

[26]  T. Pestell,et al.  MicroRNAs and cancer stem cells: the sword and the shield , 2014, Oncogene.

[27]  E-H Sun,et al.  Screening miRNAs related to different subtypes of breast cancer with miRNAs microarray. , 2014, European review for medical and pharmacological sciences.

[28]  Lana X. Garmire,et al.  A Novel Model to Combine Clinical and Pathway-Based Transcriptomic Information for the Prognosis Prediction of Breast Cancer , 2014, PLoS Comput. Biol..

[29]  Z. Zong,et al.  microRNA 490-3P enhances the drug-resistance of human ovarian cancer cells , 2014, Journal of Ovarian Research.

[30]  Yang Luo,et al.  Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel , 2014, PloS one.

[31]  O. Yersal,et al.  Biological subtypes of breast cancer: Prognostic and therapeutic implications. , 2014, World journal of clinical oncology.

[32]  D. Kemp,et al.  Selective repression of the oncogene cyclin D1 by the tumor suppressor miR-206 in cancers , 2014, Oncogenesis.

[33]  C. Goodyer,et al.  Regulation of human growth hormone receptor expression by microRNAs. , 2014, Molecular endocrinology.

[34]  Cheng Lu,et al.  Differential DNA methylation status between breast carcinomatous and normal tissues. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[35]  Giancarlo Mauri,et al.  Integration of mRNA Expression Profile, Copy Number Alterations, and microRNA Expression Levels in Breast Cancer to Improve Grade Definition , 2014, PloS one.

[36]  Zujiang Yu,et al.  Role of MicroRNA-1 in Human Cancer and Its Therapeutic Potentials , 2014, BioMed research international.

[37]  M. Dalamaga,et al.  Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: Quo vadis? , 2014, World journal of clinical oncology.

[38]  Julia B. Cordero,et al.  MicroRNA-135b Promotes Cancer Progression by Acting as a Downstream Effector of Oncogenic Pathways in Colon Cancer , 2014, Cancer cell.

[39]  F. Tas,et al.  Clinical significance of serum tenascin-C levels in breast cancer , 2014, Tumor Biology.

[40]  S. Zhong,et al.  MicroRNA-452 contributes to the docetaxel resistance of breast cancer cells , 2014, Tumor Biology.

[41]  A. Masamune,et al.  MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX. , 2014, Cellular signalling.

[42]  Yuquan Wei,et al.  Prognostic Role of MicroRNA-210 in Various Carcinomas: A Systematic Review and Meta-Analysis , 2014, Disease markers.

[43]  Chen-Yang Shen,et al.  A novel estrogen receptor-microRNA 190a-PAR-1-pathway regulates breast cancer progression, a finding initially suggested by genome-wide analysis of loci associated with lymph-node metastasis. , 2014, Human molecular genetics.

[44]  Markus Perola,et al.  Meta-analysis on blood transcriptomic studies identifies consistently coexpressed protein–protein interaction modules as robust markers of human aging , 2013, Aging cell.

[45]  S. Zhong,et al.  Down-regulation of miRNA-452 is associated with adriamycin-resistance in breast cancer cells. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[46]  Q. Jiang,et al.  [Study on miR-490-5p and miR-363 as novel biomarkers for the diagnosis of colorectal cancer]. , 2014, Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery.

[47]  S. Pinder,et al.  Aldehyde dehydrogenase and estrogen receptor define a hierarchy of cellular differentiation in the normal human mammary epithelium , 2014, Breast Cancer Research.

[48]  George Wu,et al.  RETRACTED ARTICLE: Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy , 2014, Cellular and Molecular Life Sciences.

[49]  S. Loi,et al.  Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. , 2013, Cancer treatment reviews.

[50]  F. Sun,et al.  Effects and interactions of MiR-577 and TSGA10 in regulating esophageal squamous cell carcinoma. , 2013, International journal of clinical and experimental pathology.

[51]  A. Paradiso,et al.  BRCAness: a deeper insight into basal-like breast tumors. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  Michael Golatta,et al.  Plasma MicroRNA Panel for Minimally Invasive Detection of Breast Cancer , 2013, PloS one.

[53]  Yan Yang,et al.  Loss of has-miR-337-3p expression is associated with lymph node metastasis of human gastric cancer , 2013, Journal of Experimental & Clinical Cancer Research.

[54]  Thomas D. Schmittgen,et al.  Tumor Suppressive Function of mir-205 in Breast Cancer Is Linked to HMGB3 Regulation , 2013, PloS one.

[55]  M. Rugge,et al.  The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis. , 2013, Human pathology.

[56]  R. Gambari,et al.  From microRNA functions to microRNA therapeutics: Novel targets and novel drugs in breast cancer research and treatment , 2013, International journal of oncology.

[57]  C. Arteaga,et al.  Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation , 2013, Breast Cancer Research.

[58]  G. Mauri,et al.  Combination of gene expression and genome copy number alteration has a prognostic value for breast cancer , 2013, 2013 35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).

[59]  George Wu,et al.  RETRACTED ARTICLE: Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy , 2013, Cellular and Molecular Life Sciences.

[60]  Christoph Wierling,et al.  Integrative Analysis of Cancer-Related Signaling Pathways , 2013, Front. Physiol..

[61]  Giancarlo Mauri,et al.  Copy-Number Alterations for Tumor Progression Inference , 2013, AIME.

[62]  Zhigang Yu,et al.  Decreased expression of microRNA-206 in breast cancer and its association with disease characteristics and patient survival , 2013, The Journal of international medical research.

[63]  Yu Zhou,et al.  MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells , 2013, Molecular Cancer.

[64]  J. Lebrun,et al.  MicroRNA-584 and the Protein Phosphatase and Actin Regulator 1 (PHACTR1), a New Signaling Route through Which Transforming Growth Factor-β Mediates the Migration and Actin Dynamics of Breast Cancer Cells* , 2013, The Journal of Biological Chemistry.

[65]  Chiara Romualdi,et al.  miR148b is a major coordinator of breast cancer progression in a relapse‐associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1 , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[66]  S. Zhang,et al.  Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. , 2013, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[67]  S. Dalal,et al.  Understanding the Role of Keratins 8 and 18 in Neoplastic Potential of Breast Cancer Derived Cell Lines , 2013, PloS one.

[68]  Ava Kwong,et al.  Circulating microRNAs as Specific Biomarkers for Breast Cancer Detection , 2013, PloS one.

[69]  S. Fox,et al.  Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women , 2013, Breast Cancer Research and Treatment.

[70]  F. Di Virgilio,et al.  Purines, purinergic receptors, and cancer. , 2012, Cancer research.

[71]  Yu Sun,et al.  Serum MicroRNA-155 as a Potential Biomarker to Track Disease in Breast Cancer , 2012, PloS one.

[72]  Kevin Struhl,et al.  An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state , 2012, Proceedings of the National Academy of Sciences.

[73]  C. Croce,et al.  Oncosuppressive role of p53‐induced miR‐205 in triple negative breast cancer , 2012, Molecular oncology.

[74]  R. Talhouk.  On cell-matrix interactions in mammary gland development and breast cancer. , 2012, Cold Spring Harbor perspectives in biology.

[75]  S. Yamada,et al.  N-cadherin-mediated cell–cell adhesion promotes cell migration in a three-dimensional matrix , 2012, Journal of Cell Science.

[76]  Marcel J. T. Reinders,et al.  Integration of Clinical and Gene Expression Data Has a Synergetic Effect on Predicting Breast Cancer Outcome , 2012, PloS one.

[77]  Y. Zhuang,et al.  The microRNA expression associated with morphogenesis of breast cancer cells in three-dimensional organotypic culture. , 2012, Oncology reports.

[78]  Zhi-ren Zhang,et al.  Macrophages in Tumor Microenvironments and the Progression of Tumors , 2012, Clinical & developmental immunology.

[79]  David A. Williams,et al.  RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans. , 2012, Blood.

[80]  R. Bast,et al.  Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients , 2012, Cancer.

[81]  R. Stallings,et al.  MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-β signalling pathway. , 2012, Carcinogenesis.

[82]  A. Bar-Or,et al.  Regulation of miRNA 219 and miRNA Clusters 338 and 17-92 in Oligodendrocytes , 2012, Front. Gene..

[83]  N. Saini,et al.  Downregulation of BCL2 by miRNAs augments drug-induced apoptosis – a combined computational and experimental approach , 2012, Journal of Cell Science.

[84]  T. Khoury,et al.  Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy , 2012, Modern Pathology.

[85]  R. Lyle,et al.  miR-511-3p modulates genetic programs of tumor-associated macrophages. , 2012, Cell reports.

[86]  M. Gariboldi,et al.  miRNA Profiling in Colorectal Cancer Highlights miR-1 Involvement in MET-Dependent Proliferation , 2012, Molecular Cancer Research.

[87]  B. A. Carter,et al.  Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group , 2012 .

[88]  R. Tiwari,et al.  Hypoxia and estrogen are functionally equivalent in breast cancer-endothelial cell interdependence , 2012, Molecular Cancer.

[89]  Ben Tran,et al.  Luminal-B breast cancer and novel therapeutic targets , 2011, Breast Cancer Research.

[90]  C. Caldas,et al.  Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance , 2011, Breast Cancer Research.

[91]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[92]  Hemant Ishwaran,et al.  Signalling pathway for RKIP and Let‐7 regulates and predicts metastatic breast cancer , 2011, The EMBO journal.

[93]  M. Ellis,et al.  Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors , 2011, Steroids.

[94]  Gabriele Sales,et al.  parmigene - a parallel R package for mutual information estimation and gene network reconstruction , 2011, Bioinform..

[95]  Edith A Perez,et al.  MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. , 2011, Trends in molecular medicine.

[96]  P. Marcato,et al.  Aldehyde dehydrogenase: Its role as a cancer stem cell marker comes down to the specific isoform , 2011, Cell cycle.

[97]  Mingli Liu,et al.  Role of Notch and its oncogenic signaling crosstalk in breast cancer. , 2011, Biochimica et biophysica acta.

[98]  H. Su,et al.  [Expression profiles of microRNAs in radioresistant esophageal cell line]. , 2011, Zhonghua yi xue za zhi.

[99]  Alain Chédotal,et al.  Novel roles for Slits and netrins: axon guidance cues as anticancer targets? , 2011, Nature Reviews Cancer.

[100]  Peter Carmeliet,et al.  Hypoxia and inflammation. , 2011, The New England journal of medicine.

[101]  V. Cryns,et al.  Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. , 2011, Molecular endocrinology.

[102]  L. Esserman,et al.  Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics , 2011, Expert review of molecular diagnostics.

[103]  Hongling Li,et al.  miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1 , 2011, Breast Cancer Research and Treatment.

[104]  Anders Krogh,et al.  miR-449 inhibits cell proliferation and is down-regulated in gastric cancer , 2011, Molecular Cancer.

[105]  Jian Huang,et al.  Incorporating higher-order representative features improves prediction in network-based cancer prognosis analysis , 2011, BMC Medical Genomics.

[106]  S. Cole,et al.  Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study , 2010, Clinical Cancer Research.

[107]  Brigitte Rack,et al.  Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer , 2010, Breast Cancer Research.

[108]  F. Stossi,et al.  Genomic Collaboration of Estrogen Receptor α and Extracellular Signal-Regulated Kinase 2 in Regulating Gene and Proliferation Programs , 2010, Molecular and Cellular Biology.

[109]  Jorge S. Reis-Filho,et al.  Molecular Profiling: Moving Away from Tumor Philately , 2010, Science Translational Medicine.

[110]  Adrian V. Lee,et al.  Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer , 2010, Breast Cancer Research.

[111]  Justin Zobel,et al.  Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context , 2010, BMC Bioinformatics.

[112]  D. Dabbs,et al.  Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy , 2010, Cancer.

[113]  A. Ashworth,et al.  FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. , 2010, Cancer research.

[114]  J. Fridman,et al.  Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors , 2010, Molecular Cancer Therapeutics.

[115]  K. Kashiwagi,et al.  Modulation of cellular function by polyamines. , 2010, The international journal of biochemistry & cell biology.

[116]  Y. Qi,et al.  Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate , 2010, Breast Cancer Research and Treatment.

[117]  F. Heitz,et al.  Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. , 2009, European journal of cancer.

[118]  T. Traina,et al.  Targeting insulin-like growth factor type 1 receptor in cancer therapy , 2009, Targeted Oncology.

[119]  Jeannette Y. Wick,et al.  An overview of small-molecule inhibitors of VEGFR signaling , 2009, Nature Reviews Clinical Oncology.

[120]  L. Carey,et al.  Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. , 2009, Clinical breast cancer.

[121]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[122]  Andrea Ventura,et al.  MicroRNAs and Cancer: Short RNAs Go a Long Way , 2009, Cell.

[123]  Iris Barshack,et al.  MiR‐92b and miR‐9/9* Are Specifically Expressed in Brain Primary Tumors and Can Be Used to Differentiate Primary from Metastatic Brain Tumors , 2008, Brain pathology.

[124]  Christophe Lemetre,et al.  MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer , 2009, Breast Cancer Research.

[125]  N. Kondo,et al.  miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. , 2009, Cancer research.

[126]  A. Corti,et al.  Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNγ , 2008, Molecular Cancer Therapeutics.

[127]  Robert Johansson,et al.  Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker. , 2008, Carcinogenesis.

[128]  B. Calvo,et al.  Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  W. Gerald,et al.  Endogenous human microRNAs that suppress breast cancer metastasis , 2008, Nature.

[130]  Guo-Min Li,et al.  Mechanisms and functions of DNA mismatch repair , 2008, Cell Research.

[131]  Asli Silahtaroglu,et al.  Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. , 2007, Cancer research.

[132]  B. White,et al.  The Micro-Ribonucleic Acid (miRNA) miR-206 Targets the Human Estrogen Receptor-α (ERα) and Represses ERα Messenger RNA and Protein Expression in Breast Cancer Cell Lines , 2007 .

[133]  C. Benz,et al.  Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125b* , 2007, Journal of Biological Chemistry.

[134]  B. White,et al.  The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. , 2007, Molecular endocrinology.

[135]  Andy Liaw,et al.  Classification and Regression by randomForest , 2007 .

[136]  C. Benz,et al.  Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies , 2006, Molecular Cancer.

[137]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[138]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[139]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[140]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[141]  T. Eberlein.  A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer , 2006 .

[142]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[143]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[144]  P. Dell’Era,et al.  Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. , 2005, Cytokine & growth factor reviews.

[145]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy , 2005, Nature Medicine.

[146]  C. Osborne,et al.  Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu , 1992, Breast Cancer Research and Treatment.

[147]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[148]  Therese Sørlie,et al.  Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. , 2004, European journal of cancer.

[149]  William D. Foulkes,et al.  Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .

[150]  C. Croce,et al.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[151]  A. Kraskov,et al.  Estimating mutual information. , 2003, Physical review. E, Statistical, nonlinear, and soft matter physics.

[152]  L. Bégin,et al.  Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.

[153]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[154]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[155]  Sreekanth H. Chalasani,et al.  A Chemokine, SDF-1, Reduces the Effectiveness of Multiple Axonal Repellents and Is Required for Normal Axon Pathfinding , 2003, The Journal of Neuroscience.

[156]  J. Kurebayashi,et al.  Hypoxia Reduces Hormone Responsiveness of Human Breast Cancer Cells , 2001, Japanese journal of cancer research : Gann.

[157]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[158]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[159]  T. Barbui,et al.  The Effect of Very-low-dose Warfarin on Markers of Hypercoagulation in Metastatic Breast Cancer: Results from a Randomized Trial , 1998, Thrombosis and Haemostasis.

[160]  Z. Madhun,et al.  P2-purigenic receptors regulate phospholipase C and adenylate cyclase activities in immortalized Schwann cells. , 1996, The Biochemical journal.

[161]  Chenqi Zhao,et al.  Hormonal and Feedback Regulation of Putrescine and Spermidine Transport in Human Breast Cancer Cells (*) , 1995, The Journal of Biological Chemistry.

[162]  Chenqi Zhao,et al.  Inorganic Cation Dependence of Putrescine and Spermidine Transport in Human Breast Cancer Cells (*) , 1995, The Journal of Biological Chemistry.

[163]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[164]  J. Bonneterre,et al.  Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. , 1993, European journal of cancer.

[165]  R. Tiwari,et al.  Who is (are) the author(s) , 1977 .